Margo Shoup to join Western Connecticut Health Network as network chair of cancer service line

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Western Connecticut Health Network has announced the appointment of Margo Shoup as the new network chair of the cancer service line. Shoup will provide strategic and clinical leadership for all aspects of WCHN’s cancer services, including medical oncology and subspecialty practices.

In her role as network chair, Shoup will oversee the integration of cancer services, especially as WCHN forms a new, unified innovative health system with Health Quest, to be called Nuvance Health. Cancer services include diagnostic imaging, genetic counseling, medical oncology, radiation oncology, surgical oncology, research and clinical trials, and support services.

Shoup will also develop multidisciplinary disease management teams. Specialists and services dedicated to specific types of cancer will wrap around patients. Patients will have the most advanced and expert diagnoses, treatments, and care plans delivered expeditiously and conveniently in the same health network.

Shoup will also manage the first-of-its-kind cancer care collaboration with Memorial Sloan Kettering Cancer Center that successfully launched at Norwalk Hospital in 2017. The aim of the unique collaboration is to accelerate access to the newest cancer treatments for residents of Fairfield County, Connecticut. To learn more about MSK physicians at Norwalk Hospital visit MSKatNorwalk.org.

Shoup currently serves as president of the Central Surgical Association, and treasurer of the Western Surgical Association. She is also a member of the Society for Surgical Oncology, the Society of University Surgeons, and the Southern Surgical Association.

From 2012 to 2018, she was a director of the American Board of Surgery, as the representative for the American College of Surgeons.

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login